<DOC>
	<DOCNO>NCT00260832</DOCNO>
	<brief_summary>The purpose study compare result old patient newly diagnose secondary acute myeloid leukemia ( AML ) either receive decitabine patient 's choice physician 's advice either cytarabine supportive care medication .</brief_summary>
	<brief_title>Trial Decitabine Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Must diagnose acute myeloid leukemia . 2 . Must life expectancy least 12 week . 3 . Must sign inform consent . 1 . Must acute promyelocytic leukemia ( M3 classification ) 2 . Must active systemic malignancy . 3 . Must inaspirable bone marrow . 4 . Must receive previous chemotherapy ( except hydroxyurea ) myeloid disorder . 5 . Must chronic respiratory disease require continuous oxygen use . 6 . Must receive experimental drug within 4 week randomization . 7 . Must candidate bone marrow stem cell transplant within 12 week randomization . 8 . Must know HIV .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Dacogen</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Poor intermediate-risk cytogenetics</keyword>
</DOC>